title: An evaluation of immune system cell infiltrate in the cervical stroma of patients with grade III cervical intraepithelial neoplasia after treatment with intralesional alpha-2B interferon.
abstract: The aim of this study was to characterize infiltrating immune cells in cervical stroma biopsy samples from patients diagnosed with cervical intraepithelial neoplasias (CINs) who were treated with IFN-alpha 2b. The authors studied 13 volunteers who were diagnosed with Cervical intraepithelial neoplasia CIN II or III and who received intra-lesional treatment with IFN-alpha 2b. They collected pre- and post-treatment biopsies from each patient. They also examined the slides under a common optical microscope with a X400 lens for biopsy sample sections that were labeled with immunohistochemistry for T lymphocyte, B lymphocyte, natural killer cell, macrophage, iNOS, and perforin markers. The presence of immune response cells in the lesion was observed after treatment with intralesional IFN-alpha 2b in patients with CIN II/III changes, a reduction in CD4+ and CD8+ T lymphocyte infiltration in the women who responded well to treatment. However, there was a significant increase in these markers in samples from women who did not respond to treatment. Nonetheless, immunotherapy with IFN-alpha 2b administered intralesionally in patients with CIN II/III yields favorable results in patients who do not smoke.
authors.forename: F A
authors.initials: FA
authors.lastname: Machado
authors.forename: D R
authors.initials: DR
authors.lastname: Abdalla
authors.forename: L
authors.initials: L
authors.lastname: Montes
authors.forename: R M
authors.initials: RM
authors.lastname: Etchebehere
authors.forename: M A
authors.initials: MA
authors.lastname: Michelin
authors.forename: E F C
authors.initials: EF
authors.lastname: Murta
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000276:immunology; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008875:Middle Aged; D060787:Neoplasm Grading; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D017211:Treatment Failure; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D002578:Uterine Cervical Dysplasia / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology
chemical_list: D015703:Antigens, CD; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins